Imunon outlines 40% trial cost reduction and early readout potential as OVATION 3 Phase III launches

Stock Information for Imunon Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Imunon Inc.

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development(TM)
Life Sciences Investor Forum: Now Available for Online Viewing
Life Sciences Investor Forum Agenda Announced for June 11th-12th
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.